Renee. well multiple payers, they product and Thanks, we studies of clinical key conducting approvals agility product as across and to team, objectives clinical R&D commercial launches, regulatory of two Recently achieved the as We're key reviews, and with fully in implemented with as quickly virtual mitigated programs. a the Germany. virtual pleased commercial, our challenges with organizations, including the engagements advancement launch FDA successfully physicians pivoted regulatory and our and
patients number volume strong the and performance patient XXXX, quarter, of durability compared growth, patient the average team innovation compliance, X% reflecting strong Xyrem to of the with the quarter in Our of period same reflects operational XX,XXX. our increased resilience active continued products. Xyrem and to this the In and persistence, increasing our second X%,
average impacted the of by new and COVID-XX. patients on were diagnoses enrollments While therapy patient increased, number
New shifts There the they in quarter. quarter. upward were half of late but during of latter second decline meaningful the in in first XXXX, quarter patient to the began mix payer trended enrollments no the the second
treatment to with COVID-XX increase We're the programs. initially be flow. for accounting of for top and of fourth on centers for second but believe enrollment Xywav, we to that of following quarter, half option levels the XX% Xywav and reopen patient observe very launching of important oxybate we gradually the will for implementation. will the accommodate and a However, assistance the of more brands patients by timely to reaching the an forward low new may pleased approval in the become as patient look during represents Launch believe prescribers, We did will improve new continue patient the this activities Xywav treatment sleep year, demand learn approximately in significant Xyrem choice. focus oxidate X,XXX existing Xyrem We narcolepsy joint use. patients sodium advance management impacted
sodium label, Xywav. of Xywav and in will seamlessly understand flexible ability transition significantly at approach oxybate narcolepsy the Xyrem of Our existing availability lower aimed a the be product patients for treaters to the patients, to the the dosing ensuring benefits data their
of treatment is for newly patients oxybate the Xyrem to majority And previously on including concerns, Xywav prescribed Xywav have by goal for of and Xyrem oxybate become patients, Our choice were patients, diagnosed not patients current the sodium patients. based narcolepsy who to XXXX. on all
expect to be broaden idiopathic to population with indication. hypersomnia treated also We patient meaningfully the able an
launch to access at prescribers and a access, to on providing and pricing the programs, broad include of made Xywav the efforts product. parity obtaining low sodium has patients payer robust Our ensure ensure coverage, and patient successful of the to considered price patient educating benefits a To we carefully Xyrem. strong decision
and timely major for managed payers to with with intention contract broad to the Our care working obtain coverage. is Xywav team all already
will fourth quarter initiatives, and we information the on educational approach this treatment efforts. Xywav be of the and will as We investor launch, narcolepsy, in webcasts commercial include update hosting
to backdrop we reduction now its We increase physicians prescriptions, to impact the observe to Against patient this the new first office quarter Sunosi. start in and Sunosi strong the including COVID-XX did and continue refills. pleased of visits, on compared were XX% of a patient U.S. of in stage that Turning despite a XXXX, diagnoses. new at patients launch,
First included gross-to-net. in these were net inter variability half million, sales quarter and XXXX XX
second expect analog the XXXX XXXX half the GTNs fall half half growth XX% We range. the growth expect of the TRX closely over within track in to to sales to first second year XX% more the and
initial feedback from Germany launch look positive we forward uptake May, in to prescribers the launch countries and XX rolling over the continuing narcolepsy Additionally, months. and with the our European we're following pleased other in in next
we're interactions efforts, with use have telemedicine awareness campaigns prescriptions, launch we our during and through also campaign restarted a of face digital commencing have We're media number has target as driving the digital where prescribers. of seen face part COVID-XX. through portals, As we increasing pilot increased of to
portfolio, oncology launch the the to to give of on Turning I'm an update pleased Zepzelca. you very
treatment distributors As FDA relapsed received orders – the of cancer. patients approved X, by became to commercially you we Zepzelca know, available on was for and becomes June July commercially with cell lung available in Zepzelca that small launch this product. excellent of the for teams, functional six of months day. same cross access medical, and everyone prepared market us I a sales, want robust that acknowledge to collaborative our and marketing, Zepzelca approach within involved licensing all
of X,XXX strong small and phase promising. centers efficacy focused academic new more on for its top is initial prescribers cancer we're across to from lung the demand the launch, During profile. engaging treatment and we’re cell XXX safety option and a The Zepzelca’s interest with than very initial seeing with monotherapy community date physicians Zepzelca and
treatment [dossier] submitting to believe a guidelines recommended early to reflected patients months importance systemic our approval cancer clinical compelling product along of So Zepzelca and quickly been has the addition is therapy. for relapse for expedited the small in that same lung that affairs the on additional reflects prior a for the of with in the preferred new approval. Zepzelca treatment added up following this patients who cell relapse fact options of relapse to treatment NCCN their We guideline the cancer six need July indication Zepzelca patients. following the lung this cell for profile day data team and small scientific the
issues. PBL, the to Erwinaze manufacturer and to turning sole Now, have owner continues quality manufacturing and
availability to Given one second in – market this was product U.S. quarter. limited the the than week less availability in
unrelated expect of supply to the to global the significant remainder for COVID-XX. disruptions year, We continue
for through significant revenue our to manifests deliver I high drives recombinant we on bring quality on an important up patients itself possible. Rob or and this over significantly market, launches to to XXXX as asparaginase multiple In the we bringing near to on our summary, to new call innovative as and is on and our their as now quickly update will execute a to in long-term focus products turn financials, are five development Although shortage JCP-XXX, XXXX to key and programs. the more impact indications the families track market.
